Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Read More…
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Phone805-562-3500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$68.13 million
Profitability
Miscellaneous
Employees259
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Sientra (NASDAQ:SIEN) Frequently Asked Questions
What is Sientra's stock symbol?
Sientra trades on the NASDAQ under the ticker symbol "SIEN."
How were Sientra's earnings last quarter?
Sientra Inc (NASDAQ:SIEN) posted its earnings results on Thursday, August, 8th. The medical instruments supplier reported ($1.19) EPS for the quarter, missing the Zacks' consensus estimate of ($0.69) by $0.50. The medical instruments supplier had revenue of $20.53 million for the quarter, compared to analysts' expectations of $19.04 million. Sientra had a negative return on equity of 123.80% and a negative net margin of 151.96%. The firm's revenue for the quarter was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.73) earnings per share. View Sientra's Earnings History.
When is Sientra's next earnings date?
What guidance has Sientra issued on next quarter's earnings?
Sientra updated its FY 2019 earnings guidance on Thursday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $79-83 million, compared to the consensus revenue estimate of $81.13 million.
What price target have analysts set for SIEN?
8 equities research analysts have issued 1-year price targets for Sientra's shares. Their forecasts range from $10.00 to $27.00. On average, they expect Sientra's stock price to reach $15.75 in the next year. This suggests a possible upside of 141.9% from the stock's current price. View Analyst Price Targets for Sientra.
What is the consensus analysts' recommendation for Sientra?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sientra in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sientra.
Has Sientra been receiving favorable news coverage?
Media stories about SIEN stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sientra earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned media coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Sientra.
Are investors shorting Sientra?
Sientra saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 3,200,000 shares, an increase of 10.3% from the August 30th total of 2,900,000 shares. Based on an average daily trading volume, of 969,200 shares, the days-to-cover ratio is presently 3.3 days. Approximately 7.5% of the company's shares are short sold. View Sientra's Current Options Chain.
Who are some of Sientra's key competitors?
Some companies that are related to Sientra include Inogen (INGN), Establishment Labs (ESTA), Invacare (IVC), RTI Surgical (RTIX), ConforMIS (CFMS), Lakeland Industries (LAKE), Histogenics (HSGX), Rewalk Robotics (RWLK), Precision Therapeutics (POAI), COLLPLANT HOLDI/S (CLGN), NanoVibronix (NAOV), Wound Management Technologies (WNDM), Bionik Laboratories (BNKL), Allied Healthcare Products (AHPI) and Ocugen (OCGN).
What other stocks do shareholders of Sientra own?
Who are Sientra's key executives?
Sientra's management team includes the folowing people:
- Mr. Jeffrey M. Nugent, Chairman & CEO (Age 72)
- Mr. Charles Huiner, COO and Sr. VP of Corp. Devel. & Strategy (Age 48)
- Mr. Keith J. Sullivan, Director & Advisor to MiraDry Bus. (Age 61)
- Mr. Paul Sean Little, CFO, Sr. VP & Treasurer (Age 54)
- Ms. Deborah Bettencourt, VP of Customer Experience & Corp. Admin.
How do I buy shares of Sientra?
Shares of SIEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Sientra's stock price today?
One share of SIEN stock can currently be purchased for approximately $6.51.
How big of a company is Sientra?
Sientra has a market capitalization of $320.88 million and generates $68.13 million in revenue each year. The medical instruments supplier earns $-82,630,000.00 in net income (profit) each year or ($3.25) on an earnings per share basis. Sientra employs 259 workers across the globe.View Additional Information About Sientra.
What is Sientra's official website?
How can I contact Sientra?
Sientra's mailing address is 420 SOUTH FAIRVIEW AVENUE SUITE 200, SANTA BARBARA CA, 93117. The medical instruments supplier can be reached via phone at 805-562-3500 or via email at [email protected]
MarketBeat Community Rating for Sientra (NASDAQ SIEN)
MarketBeat's community ratings are surveys of what our community members think about Sientra and other stocks. Vote "Outperform" if you believe SIEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SIEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
